Valuation: MaxCyte, Inc.

Market Cap 164M 147M 135M 122M 229M 15.58B 233M 1.61B 647M 8.2B 616M 603M 25.85B P/E 2026 *
-5.8x
P/E 2027 * -6.24x
Enterprise Value 34.57M 30.96M 28.48M 25.81M 48.24M 3.28B 49.14M 340M 136M 1.73B 130M 127M 5.45B EV / Sales 2026 *
1.07x
EV / Sales 2027 * 1.5x
Free-Float
92.11%
Yield 2026 *
-
Yield 2027 * -
1 day-8.09%
1 week+13.57%
Current month+41.96%
1 month+41.96%
3 months+51.43%
6 months+80.68%
Current year+2.58%
1 week 1.36
Extreme 1.3649
1.76
1 month 0.94
Extreme 0.93605
1.76
Current year 0.64
Extreme 0.6434
1.76
1 year 0.64
Extreme 0.6434
1.8
3 years 0.64
Extreme 0.6434
5.54
5 years 0.64
Extreme 0.6434
12.99
10 years 0.64
Extreme 0.6434
17.44
Manager TitleAgeSince
Chief Executive Officer 51 2023-12-31
Director of Finance/CFO 57 2026-03-29
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 70 2004-02-29
Director/Board Member 78 2004-12-31
Director/Board Member 67 2015-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
6/17/26 Free

Chairman

80,000 0.0747%
4/15/26 Free

Chief Financial Officer

187,500 0.1755%
3/30/26 Free

Chief Financial Officer

375,000 0.3515%
Change 5-day change 1-year change 3-year change Capi.($)
-8.09%+13.57%+5.30%-46.28% 164M
-1.72%+3.44%+25.31%+60.56% 258B
-2.00%+0.75%+7.99%+25.46% 163B
-3.73%-4.48%-18.49%+67.13% 150B
-1.66%-8.12%-58.26%-16.12% 60.84B
-2.57%+3.30%+10.22%+47.55% 53.03B
0.00%+2.46%-11.97%-6.29% 53.31B
-3.47%+1.04%+21.98%+72.85% 49.3B
+0.84%-3.12%+9.80%+64.47% 50.67B
-3.61%+1.99%+34.94%+95.49% 45.46B
Average -2.60%+1.08%+2.68%+36.48% 88.36B
Weighted average by Cap. -2.10%+0.15%+5.19%+47.78%

Financials

2026 *2027 *
Net sales 32.2M 28.84M 26.52M 24.03M 44.92M 3.06B 45.76M 316M 127M 1.61B 121M 118M 5.07B 37.2M 33.31M 30.64M 27.76M 51.9M 3.53B 52.87M 365M 147M 1.86B 140M 137M 5.86B
Net income -29.33M -26.26M -24.16M -21.89M -40.92M -2.78B -41.68M -288M -116M -1.46B -110M -108M -4.62B -27.67M -24.78M -22.8M -20.66M -38.61M -2.63B -39.34M -272M -109M -1.38B -104M -102M -4.36B
Net Debt -130M -116M -107M -96.68M -181M -12.3B -184M -1.27B -511M -6.47B -486M -476M -20.4B -108M -96.97M -89.2M -80.82M -151M -10.28B -154M -1.06B -427M -5.41B -406M -398M -17.06B
Projected Income Statement - Annual - MaxCyte, Inc.
Logo MaxCyte, Inc.
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
Employees
91
Date Price Change Volume
26-10-30 US$1.590 -8.09% 963,824
26-10-29 US$1.730 +1.17% 1,142,242
26-10-28 US$1.710 +11.04% 1,709,281
26-10-27 US$1.540 +1.99% 1,578,409
26-10-26 US$1.510 +7.86% 1,129,384
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - MaxCyte, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.590USD
Average target price
4.108USD
Spread / Average Target
+158.33%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - MaxCyte, Inc.
  1. Stock Market
  2. Stocks
  3. MXCT Stock